Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials.
The study looked at long-term outcomes in patients treated with guselkumab 100 mg every eight weeks. Authors for the analysis used Investigator’s Global Assessment of cleared or minimal disease (IGA 0/1) and Psoriasis Area and Severity Index (PASI) 90 responses from weeks 100 to 252 as primary metrics. Patients were stratified by initial disease severity (baseline PASI, IGA, body surface area) and prior treatment exposure (phototherapy, nonbiologic, biologic therapies).
Response rates were consistent across all groups. IGA 0/1 responses ranged from 82.0% to 85.4% for PASI <20 and from 81.1% to 81.4% for PASI ≥20. Similar trends were present for PASI 90 responses, with rates of 78.6%-81.1% and 81.4%-83.8%, respectively. Baseline IGA scores, BSA percentages, and prior treatment exposures had negligible effects on long-term efficacy. Notably, patients without prior biologic use showed slightly higher IGA 0/1 (83.2%-85.3%) and PASI 90 (82.2%-83.8%) responses compared to those with prior biologic exposure (75.3%-79.5% and 71.2%-76.3%).
"Durable guselkumab efficacy was sustained through 5 years of treatment among patient subpopulations irrespective of baseline disease severity or prior treatment history," the authors wrote.
Source: Gordon K, et al. J Drugs Dermatol. 2025;24(2):196-202. Doi:10.36849/JDD.8344